HCPCS code J1171: Hydromorphone billing after J1170’s deletion

Key takeaways

HCPCS code J1171 (injection, hydromorphone, 0.1 mg) is the active code for injectable hydromorphone, effective October 1, 2024.

J1170 (injection, hydromorphone, up to 4 mg) was deleted effective September 30, 2024, and claims carrying it are returned unprocessed.

One J1171 unit equals 0.1 mg, so a 2 mg dose bills as 20 units rather than the single unit J1170 took.

J3490 is no longer an appropriate fallback for hydromorphone, because a specific replacement code now exists.

Every J1171 claim needs the 11-digit NDC from the vial administered plus either the JW or the JZ wastage modifier.

Pabau’s claims management software captures drug name, NDC, dose, and route at the point of care, so the claim matches the record.

Hydromorphone injections no longer bill under J1170.

CMS deleted that code effective September 30, 2024, and replaced it with HCPCS code J1171, which became billable on October 1, 2024. The descriptor tightened from “up to 4 mg” to “0.1 mg”, so the unit math changed on every claim.

The unit change is where these claims break most often. A 2 mg dose was a single unit under the old code. Under J1171 the same dose is 20 units. On a physician-administered drug the code, the units, and the NDC all have to agree on the line. This guide covers J1171 end to end: code details, unit calculation, reimbursement, NDC reporting, documentation, and the denial triggers the transition created.

J1170 is deleted and J1171 replaced it

CMS retired J1170 in the October 2024 quarterly HCPCS update, with a deletion date of September 30, 2024. The same update added J1171 for the same drug at a finer billing increment. Medicare Administrative Contractors including CGS and Noridian published the change. State Medicaid programs issued crosswalk bulletins mapping the discontinued code to its replacement.

One date causes recurring confusion. Some code references list J1171 with a January 1, 2025 date, which is simply the first annual codebook year that printed it. The effective and billable date is October 1, 2024. Some practices held fourth-quarter 2024 claims while waiting for a 2025 start date. Those claims should have gone out under J1171.

For any date of service on or before September 30, 2024, J1170 remains the correct code on a corrected claim or an appeal. Code selection follows the date the drug was administered, not the date you file.

HCPCS code J1171: Definition and code details

HCPCS code J1171 is the Level II code assigned to the injection of hydromorphone, 0.1 mg. The Centers for Medicare and Medicaid Services (CMS) maintains HCPCS Level II codes for drugs, supplies, and other items that CPT does not cover. J-codes specifically cover physician-administered injectable drugs billed on the CMS-1500 claim form or its electronic equivalent.

The table below summarizes the key attributes of J1171 as maintained in the CMS HCPCS code files.

How to calculate J1171 billing units

Multiply the milligrams administered by ten. One unit of J1171 equals 0.1 mg, so 1 mg is 10 units and 2 mg is 20 units. This is the single largest behavioral change from the old code, where any dose up to 4 mg collapsed into one unit.

The table below converts the doses outpatient practices give most often. Report units for the amount actually administered to the patient, and report any discarded amount separately with the JW modifier.

Doses that fall between 0.1 mg increments still need a whole number of units. A 0.75 mg dose is 7.5 units of drug. Most payers require you to round that to the nearest reportable unit under their own policy. Check your MAC’s guidance rather than rounding by habit, and document the administered milligrams precisely so the two figures can be reconciled.

Drug information: Hydromorphone (Dilaudid)

Hydromorphone is a potent opioid analgesic and a Schedule II controlled substance under the Drug Enforcement Administration’s classification system. It is roughly five to eight times more potent than morphine on a milligram-per-milligram basis. Typical outpatient doses run from 0.2 mg to 2 mg, well below the old 4 mg ceiling. The 0.1 mg unit in J1171 describes the drug far more accurately.

Dilaudid is the primary brand name for injectable hydromorphone. Generic versions from multiple manufacturers also carry National Drug Codes that crosswalk to J1171. Clinical use cases for injectable hydromorphone in outpatient settings include acute pain management in oncology, post-procedural pain, and palliative care where oral opioids are insufficient.

• Drug class: Opioid agonist (mu-receptor)
• DEA schedule: Schedule II (high potential for abuse, accepted medical use with severe restrictions)
• Formulations billed under J1171: Single-dose vials and multi-dose vials of hydromorphone HCl for injection
• Brand name: Dilaudid (primary); generic formulations are widely available
• Onset: Approximately 5 minutes IV; 15 minutes IM or SC

Hydromorphone is a Schedule II controlled substance, so the practice administering it must hold DEA registration. It must also comply with state pharmacy regulations and keep detailed controlled substance logs. These requirements operate independently of the HCPCS billing process. They still shape the documentation that supports medical necessity on claims.

Medicare reimbursement for HCPCS code J1171

Medicare reimburses J1171 under the Average Sales Price (ASP) methodology. CMS calculates ASP quarterly from manufacturer-reported sales data, then sets the payment rate at ASP plus 6%. That 6% add-on covers the practice’s acquisition cost, handling, and storage overhead for the drug.

Compare payment per dose, not per unit, when you review the transition. The J1171 per-unit rate covers 0.1 mg, so it is a fraction of the old J1170 per-unit rate that covered up to 4 mg. A rate that looks like a steep cut on a fee schedule line usually resolves once you multiply it by the correct unit count.

Payment rates change each quarter. The applicable rate is set by the quarter in which the drug is administered, not the quarter in which the claim is submitted. Pull current ASP pricing from the CMS average sales price files before setting internal charge amounts.

Tracking reimbursement across quarters matters for practices that routinely administer injectable drugs. Small shifts in ASP affect net margin on every administered dose.

Medicaid and commercial payers set their own rates independently of Medicare ASP methodology. Some managed care plans reimburse at a percentage of Medicare ASP. Others apply a fixed fee schedule or require prior authorization before the drug is administered. Verify payer-specific policy before administering a controlled substance injectable.

NDC to HCPCS crosswalk for J1171

CMS requires every claim for a physician-administered drug to carry the 11-digit National Drug Code (NDC) of the product administered. Report the NDC with the N4 qualifier in loop 2410 of the 837P electronic transaction. On the paper CMS-1500 form it goes in the shaded portion of box 24.

The crosswalk for J1171 includes multiple NDC numbers covering different manufacturers, concentrations, and package sizes. The table below lists product codes from one common manufacturer, with the unit count each vial produces. The claim itself carries the full 11-digit code from the vial, so add the package segment printed on the label. Verify the crosswalk against current CMS quarterly NDC files rather than cached practice data.

Billing unit calculation: One unit of J1171 covers 0.1 mg of hydromorphone. A 2 mg dose is 20 units. A 6 mg dose is 60 units. Reporting a single unit for any dose above 0.1 mg was normal practice under J1170. It now underreports the drug given, and it fails a records-to-claim reconciliation.

Covered ICD-10 diagnosis codes for hydromorphone injections

Every J1171 claim must include at least one ICD-10-CM diagnosis code that establishes medical necessity. Medicare Administrative Contractors may apply Local Coverage Determinations that specify which diagnoses support coverage for injectable opioids. The most commonly accepted diagnoses fall into acute and chronic pain categories.

Sequence the diagnosis codes to reflect the condition driving the encounter. When a patient presents for cancer pain management, code the underlying neoplasm first and the pain (G89.3) as a secondary diagnosis. Sequencing errors are a leading cause of medical necessity denials on J-code claims. Our ICD-10-CM codes reference carries the full descriptor and the coding notes for each diagnosis above. Appeals on these cases usually need the clinical note as supporting documentation.

Billing guidelines and documentation requirements

Documentation for J1171 serves two functions. It satisfies payer audit requirements, and it supports the clinical record if the claim is reviewed. Practices must keep a contemporaneous record of the administration that matches the billing data on the claim, including the unit count.

For Schedule II injectables, the clinical record and the controlled substance log must both support the dose billed. An inconsistency between the two is an audit finding.

• Drug name and formulation: Record the full drug name (hydromorphone HCl), concentration, and manufacturer as printed on the vial label
• Dose administered: Document the exact number of milligrams given, not just the vials used
• Units billed: Record the J1171 unit count and show that it equals the milligrams administered multiplied by ten
• Route of administration: Specify IV, IM, or SC so the clinical record matches the billing intent
• Time and date: Log the exact administration time; controlled substance records require it and audits review it
• NDC number: Record the 11-digit NDC from the vial administered, not from memory or a master list
• Prescribing provider: Identify the supervising physician or provider authorizing the administration
• Medical necessity statement: Include a clinical note explaining why injectable hydromorphone was chosen over alternative analgesics

Applicable modifiers

Modifiers give the claim line context that affects payment and audit risk. The table below lists the modifiers most often used with J1171 and when each one applies.

JW and JZ are mandatory for Medicare drug waste reporting. Omitting both when billing from a single-dose vial is a common source of clean claim failures. The finer J1171 unit also makes wastage arithmetic more visible. A 2 mg vial with 1.5 mg given splits into 15 administered units and 5 discarded units. Set a standard procedure for documenting wastage at the point of administration rather than after the fact.

By this point the J1171 claim line has five fields on it, and they all have to agree with each other and with the vial. The worked example below runs a 2 mg dose through all five.

Common billing errors and how to avoid them

Hydromorphone billing carries a higher audit profile than most J-codes. It involves a Schedule II controlled substance, it relies on ASP pricing that changes quarterly, and it changed codes and units in late 2024. The errors below account for the majority of denials on these claims.

• Submitting the deleted code: Any claim reporting J1170 for a date of service after September 30, 2024 is returned to the provider unprocessed. Retire the code in the charge master and in any claim template, not just on the claim in front of you.
• Units still calculated on the old 4 mg increment: The most likely error of the transition. One unit for a 2 mg dose was correct under J1170 and underreports the dose under J1171, which needs 20 units. Multiply the milligrams administered by ten.
• Defaulting to J3490: The unclassified drug code was a reasonable stopgap only while no specific code existed. J1171 exists, so J3490 now triggers a denial and a request for a narrative you did not need to write.
• Missing or invalid NDC: A frequent denial trigger. The 11-digit NDC must match the vial administered, formatted as 5-4-2 digits in the N4 qualifier. A 10-digit NDC, or one from a different package size, generates an automatic edit.
• Wrong or missing diagnosis code: Some MACs accept R52 (pain, unspecified), while others respond with medical review or a prior authorization request. Use the most specific diagnosis code available.
• Omitting the JW or JZ modifier: Medicare requires one of the two on every claim for a drug administered from a single-dose vial. Missing both results in a claim returned to provider.
• Date of service mismatch: The date billed must match the date the drug was administered. It is not the date the order was written or the claim prepared. It also decides whether J1170 or J1171 is correct.
• Stale ASP rate: Using a prior quarter’s ASP figure in a new quarter. Rates update in January, April, July, and October, so build a quarterly refresh into your charge master workflow.

A pre-submission checklist catches most of these before the claim leaves the practice. Confirming coverage before the drug is administered catches the rest. That avoids giving a controlled substance the payer will ultimately deny.

Related HCPCS J-codes for opioid and pain management injectables

J1171 sits within a broader family of J-codes for injectable opioids and analgesics. Practices billing several pain management drugs should keep clear crosswalk documentation, so the code on the claim matches the drug in the vial. Note how much the dosage unit varies between these codes.

J3490 deserves a specific note here, because plenty of guidance written during the 2024 transition still points to it. An unclassified code is appropriate only when no specific HCPCS code describes the drug. Hydromorphone has J1171, so the unclassified code is the wrong answer for it. Confirm current status through the AAPC HCPCS Level II lookup or the CMS annual HCPCS code list before each billing cycle.

How Pabau supports J-code billing and drug administration tracking

Practices that administer physician-dispensed injectable drugs carry a documentation burden at every stage of the encounter. It covers the administration record, the controlled substance log, the charge capture, and the claim. Practice management software like Pabau is built for that kind of multi-step workflow. Pabau’s claims management software connects the clinical record to the billing output, so staff do not rekey data between systems.

Practices billing J-codes regularly need drug administration tracking inside the record itself. It records the drug name, NDC, dose, and route at the point of care. That record then populates the billing encounter, so the unit count derives from the milligrams documented rather than from a coder’s mental arithmetic. That matters most right after a unit change like the move from J1170 to J1171.

• Structured clinical templates that capture drug name, NDC, dose, route, and administration time in one form
• Charge capture rules that link the administered drug to the correct HCPCS J-code and unit basis
• Integration with clearinghouse workflows for remittance advice processing and denial tracking
• An audit trail for administered drugs that supports both payer audits and DEA controlled substance compliance

Generating accurate superbills that carry the J-code, NDC, units, and diagnosis codes is where manual billing workflows tend to break down. Pabau structures the encounter so each of those data points is captured once, at the source, instead of being reconstructed from partial notes.

Reduce J-code billing errors with Pabau

Pabau’s claims management software connects drug administration records to billing workflows, so NDC numbers, dosage units, and diagnosis codes flow through to the claim automatically. See how it works for outpatient injection practices.

Book a demo

Conclusion

The practical answer for hydromorphone billing is short. Use J1171 for dates of service from October 1, 2024 onward. Calculate units at 0.1 mg each, and leave J1170 and J3490 out of it. The work sits in the surrounding requirements: quarterly ASP pricing, mandatory NDC reporting, JW and JZ modifier selection, controlled substance documentation, and ICD-10 sequencing.

Any one of those done wrong produces a denial. On a Schedule II drug that costs rework and appeal documentation as well as delayed payment. The fix worth making first sits upstream of the coder. Capture the milligrams, the NDC, and the wastage at the point of administration, and the unit count derives itself.

Sweep the charge master once, wire the administration record to the claim, and the J1170 transition stops generating denials on its own. Book a demo to see how Pabau captures J-code administration data and carries it through to the claim.

Continue your research

Need to understand how claims flow through a clearinghouse? How medical claims clearinghouses work explains the end-to-end submission process for physician-administered drugs.

Getting denials on J-code claims? Denial codes in medical billing breaks down the most common remittance advice codes and how to respond to each one.

Want to tighten your charge capture before claims go out? How superbills work in medical billing covers what data must appear on the superbill for buy-and-bill drugs to pass payer edits.

Frequently asked questions